A large effort of this kind is already underway, although it is still largely theoretical. One important problem is determining the correct target genes for the delivery of these proteins, and how many and which are suitable. In my view, one of the biggest hurdles to overcome is getting patients to accept the idea that they may be genetically manipulated and have a genetic disease. The last major hurdle to overcome is the need to get the cells to proliferate, with a view to using a gene therapy technique like embryonic stem-cell transplantation to treat some forms of muscular pain. However, this requires a radical advance in the understanding of how stem cells function, as this would require that cells from a large number of patients be grown and harvested on an industrial scale, not only for use in drug antabuse and mental illness use in animal studies, but also in many other clinical settings where cell therapy is most widely used.
The next major milestone in gene therapy will almost certainly be the use of stem cells to produce therapeutic protein in the absence of a functional gene. As a result of the development of stem cells from adult cells, in a matter of years, a large group of people with severe arterial disease could be treated with the same treatment. It's easy to envision an enormous growth in the number and range of treatment options. The future for the rest of us is not as clear. For example, a study of genes associated with a number of diseases, including Huntington's, has shown that the presence or absence of a gene can result in differences in the response of a patient to various therapies and drugs. These results suggest that there exist gene variants that have a direct influence on how people respond to treatment.
That makes the gene as a whole a therapeutic target. It's possible that such a discovery will come very late, and maybe not for a long time. But we don't have to wait for that. It may be that this could be a model for gene therapy of peripheral arterial disease. It is a pity that the patient who was able to undergo this procedure did not have access to the full genome sequence of myostatin, for this is a gene that plays an essential role in the maintenance of normal blood vessel development in the developing heart. The study is a proof of concept and has been followed up by a larger, randomized, placebo-controlled trial.
Other promising therapeutic possibilities include the use of gene therapy to repair and regenerate damaged liver and pancreatic tissues and the targeting of genes for treatment of heart disease. These are just a sampling of the many new directions that may be open to research as the gene editing field moves forward. Gene editing of the antabuse and mental illness cancer. Stolhanski at the University of North Florida. They showed that, when injected by a single gene, the targeted gene, called CXCR4, caused cardiac regeneration by activating other stem cells that can migrate to tissues to replace those that are damaged. As a result, many of the blood vessels and the hearts they nourish can be restored to function.
Anafranil works on the central nervous system and treats obsessive compulsive disorder, panic attacks, depression, and ongoing pain.
Compazine is used to treat psychotic disorders such as schizophrenia, and in anti-emetic treatment of nausea and vertigo.
Clozaril is an atypical antipsycotic. It is used to treat schizophrenia in patients who do not respond to other medicines.
Thioridazine is used to treat psychotic disorders such as schizophrenia. It changes the actions of chemicals in your brain.
Loxitane belongs to a class of medications so called tricyclic antipsycotics. It is not know exactly how this medication works. It is used to treat schizophrenia.